In order to better understand the role of β3-AR in myeloid malignancies, we focused our attention on the effect of the β3-AR antagonist SR59230A on this type of tumor; in particular, we used K562, KCL22, HEL and HL60 myeloid leukemia cell lines and we demonstrated that β3-AR blockade results in reduced cancer cell lines survival by increasing apoptosis, especially under hypoxic conditions. The gene discussed is ADRB3; the disease is neoplasm.